Syncom Formulation (India)BOM:524470 +2.22%86 EBITDA Margin % is 27.00% as of Mar. 2026, which is 80% above its 10-year median of 15.03. GuruFocus rates BOM:524470 with a GF Score™ of 86/100 and a GF Value™ of ₹19.84 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 953 Drug Manufacturers companies, Syncom Formulation (India) ranks better than 73.56% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Syncom Formulation (India) EBITDA Margin % Related Terms
Syncom Formulation (India) EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524470 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India) EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syncom Formulation (India) (BOM:524470) has a EBITDA Margin % of 27.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syncom Formulation (India) and its competitors. This is 80% above median its historical median of 15.03. Over the past decade, Syncom Formulation (India)'s EBITDA Margin % has ranged from 9.29 to 22.24. According to the industry distribution chart, Syncom Formulation (India) ranks #252 out of 953 companies in the Drug Manufacturers industry, placing it in the top 26.4%.
Is Syncom Formulation (India)'s EBITDA Margin % too high?
Syncom Formulation (India)'s current EBITDA Margin % of 27.00% is 80% above median its 10-year median of 15.03. Over the past 10 years, this metric has ranged from a low of 9.29 to a high of 22.24. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Syncom Formulation (India)'s value of 27.00% is 115.3% above this industry median. Based on the distribution chart, Syncom Formulation (India) ranks #252 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Syncom Formulation (India) has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #252 out of 953 companies for EBITDA Margin %. This puts Syncom Formulation (India) in the upper half of its industry. The industry median EBITDA Margin % is 12.54. Syncom Formulation (India)'s value of 27.00% is 115.3% above this benchmark. Historically, Syncom Formulation (India)'s own EBITDA Margin % has ranged from 9.29 to 22.24 over the past decade. While the company's 10-year median is 15.03 vs. the industry median of 12.54, Syncom Formulation (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syncom Formulation (India)'s current EBITDA Margin % of 27.00% is 115.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syncom Formulation (India) and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current EBITDA Margin % is 27.00%, which is 80% above median its own 10-year median of 15.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹19.84, compared to a current price of ₹14.25 — trading 28.2% below its estimated fair value. The current EBITDA Margin % is 27.00%, which is 80% above median its 10-year median of 15.03 and 115.3% above the Drug Manufacturers industry median of 12.54. Syncom Formulation (India)'s overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current EBITDA Margin % is 27.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?
Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued.
The current stock price of ₹14.25 is trading 28.2% below its estimated GF Value™ of ₹19.84.
GuruFocus considers Syncom Formulation (India) to be Modestly Undervalued.
Key valuation signals for BOM:524470:
EBITDA Margin %: 27.00% (80% above median its 10-year median of 15.03)
GF Value™: ₹19.84 vs. price of ₹14.25 (28.2% below fair value)
Industry Position: 115.3% above the Drug Manufacturers median (#252 of 953)
No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
86GF Score
Get the complete analysis for BOM:524470
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524470 has been successfully added to your 
